Literature DB >> 16736518

Surface-bound anti-type II collagen-containing immune complexes induce production of tumor necrosis factor alpha, interleukin-1beta, and interleukin-8 from peripheral blood monocytes via Fc gamma receptor IIA: a potential pathophysiologic mechanism for humoral anti-type II collagen immunity in arthritis.

Mohammed Mullazehi1, Linda Mathsson, Jon Lampa, Johan Rönnelid.   

Abstract

OBJECTIVE: Type II collagen (CII) is a major component of hyaline cartilage, and antibodies against CII are found in a subgroup of patients with rheumatoid arthritis. We undertook this study to investigate whether and how antibodies directed against CII can form solid-phase immune complexes (ICs) with cytokine-inducing properties in a model theoretically resembling the situation in the inflamed joint, in which CII is exposed for interaction with anti-CII antibodies during periods of inflammation.
METHODS: Sixty-five arthritis patients with varying levels of anti-native CII antibodies and 10 healthy controls were evaluated concerning anti-CII and cytokines induced in a solid-phase IC model. Monocytes were either depleted or enriched to define responder cells. Antibodies blocking Fc gamma receptors (Fc gammaR) were used to define the responsible T cell surface receptors.
RESULTS: ICs containing anti-CII from arthritis patients induced the production of tumor necrosis factor alpha (TNFalpha), interleukin-1beta (IL-1beta), and IL-8. We found a close correlation between enzyme-linked immunosorbent assay optical density values and induction of TNFalpha (r = 0.862, P < 0.0001), IL-1beta (r = 0.839, P < 0.0001), and IL-8 (r = 0.547, P < 0.0001). The anti-CII-containing IC density threshold needed for cytokine induction differed among peripheral blood mononuclear cell donors. Anti-CII-containing IC-induced cytokine production was almost totally abolished (>99%) after monocyte depletion, and receptor blocking studies showed significant decreases in the production of TNFalpha, IL-1beta, and IL-8 after blocking Fc gammaRIIa, but not after blocking Fc gammaRIII.
CONCLUSION: These findings represent a possible mechanism for perpetuation of joint inflammation in the subgroup of arthritis patients with high levels of anti-CII. Blockade of Fc gammaRIIa and suppression of synovial macrophages are conceivable treatment options in such patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16736518     DOI: 10.1002/art.21892

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  26 in total

1.  The influence of IgG density and macrophage Fc (gamma) receptor cross-linking on phagocytosis and IL-10 production.

Authors:  Paul Gallo; Ricardo Gonçalves; David M Mosser
Journal:  Immunol Lett       Date:  2010-07-27       Impact factor: 3.685

2.  Dominant suppression of inflammation by glycan-hydrolyzed IgG.

Authors:  Kutty Selva Nandakumar; Mattias Collin; Kaisa E Happonen; Allyson M Croxford; Susanna L Lundström; Roman A Zubarev; Merrill J Rowley; Anna M Blom; Rikard Holmdahl
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-13       Impact factor: 11.205

3.  High anti-collagen type-II antibody levels and induction of proinflammatory cytokines by anti-collagen antibody-containing immune complexes in vitro characterise a distinct rheumatoid arthritis phenotype associated with acute inflammation at the time of disease onset.

Authors:  Mohammed Mullazehi; Linda Mathsson; Jon Lampa; Johan Rönnelid
Journal:  Ann Rheum Dis       Date:  2006-10-13       Impact factor: 19.103

4.  Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.

Authors:  Julie A Di Paolo; Tao Huang; Mercedesz Balazs; James Barbosa; Kai H Barck; Brandon J Bravo; Richard A D Carano; James Darrow; Douglas R Davies; Laura E DeForge; Lauri Diehl; Ronald Ferrando; Steven L Gallion; Anthony M Giannetti; Peter Gribling; Vincent Hurez; Sarah G Hymowitz; Randall Jones; Jeffrey E Kropf; Wyne P Lee; Patricia M Maciejewski; Scott A Mitchell; Hong Rong; Bart L Staker; J Andrew Whitney; Sherry Yeh; Wendy B Young; Christine Yu; Juan Zhang; Karin Reif; Kevin S Currie
Journal:  Nat Chem Biol       Date:  2010-11-28       Impact factor: 15.040

Review 5.  Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond.

Authors:  P Mark Hogarth; Geoffrey A Pietersz
Journal:  Nat Rev Drug Discov       Date:  2012-03-30       Impact factor: 84.694

6.  Cytokine induction by circulating immune complexes and signs of in-vivo complement activation in systemic lupus erythematosus are associated with the occurrence of anti-Sjögren's syndrome A antibodies.

Authors:  L Mathsson; E Ahlin; C Sjöwall; T Skogh; J Rönnelid
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

7.  Adjuvant properties of a biocompatible thermo-responsive polymer of N-isopropylacrylamide in autoimmunity and arthritis.

Authors:  Akhilesh Kumar Shakya; Ashok Kumar; Kutty Selva Nandakumar
Journal:  J R Soc Interface       Date:  2011-05-04       Impact factor: 4.118

Review 8.  Targeting the Fc receptor in autoimmune disease.

Authors:  Xinrui Li; Robert P Kimberly
Journal:  Expert Opin Ther Targets       Date:  2014-03       Impact factor: 6.902

Review 9.  Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis.

Authors:  William P Arend; Gary S Firestein
Journal:  Nat Rev Rheumatol       Date:  2012-08-21       Impact factor: 20.543

10.  FoxP3 and Bcl-xL cooperatively promote regulatory T cell persistence and prevention of arthritis development.

Authors:  Rizwanul Haque; Fengyang Lei; Xiaofang Xiong; Yuzhang Wu; Jianxun Song
Journal:  Arthritis Res Ther       Date:  2010-04-12       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.